Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells
    Peter Solár, Ján Koval, Jaromír Mikeš, Ján Kleban, Zuzana Solárová, Ján Lazúr, Ingrid Hodorová, Peter Fedoročko and Arthur J. Sytkowski
    Mol Cancer Ther August 1 2008 7 (8) 2263-2271; DOI:10.1158/1535-7163.MCT-08-0483

  • Research Articles: Therapeutics, Targets, and Development
    Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib
    Timothy P. Padera, Angera H. Kuo, Tohru Hoshida, Shan Liao, Jennifer Lobo, Kevin R. Kozak, Dai Fukumura and Rakesh K. Jain
    Mol Cancer Ther August 1 2008 7 (8) 2272-2279; DOI:10.1158/1535-7163.MCT-08-0182

  • Research Articles: Therapeutics, Targets, and Development
    Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice
    Serena Marchetti, Nienke A. de Vries, Tessa Buckle, Maria J. Bolijn, Maria A.J. van Eijndhoven, Jos H. Beijnen, Roberto Mazzanti, Olaf van Tellingen and Jan H.M. Schellens
    Mol Cancer Ther August 1 2008 7 (8) 2280-2287; DOI:10.1158/1535-7163.MCT-07-2250

  • Research Articles: Therapeutics, Targets, and Development
    Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
    Bernard M. Tijink, Toon Laeremans, Marianne Budde, Marijke Stigter-van Walsum, Torsten Dreier, Hans J. de Haard, C. René Leemans and Guus A.M.S. van Dongen
    Mol Cancer Ther August 1 2008 7 (8) 2288-2297; DOI:10.1158/1535-7163.MCT-07-2384

  • Research Articles: Therapeutics, Targets, and Development
    Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells
    Hongtao Gu, Xiequn Chen, Guangxun Gao and Hongjuan Dong
    Mol Cancer Ther August 1 2008 7 (8) 2298-2307; DOI:10.1158/1535-7163.MCT-08-0186

  • Research Articles: Therapeutics, Targets, and Development
    Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth
    Jacqueline Sayyah, Andrew Magis, David A. Ostrov, Robert W. Allan, Raul C. Braylan and Peter P. Sayeski
    Mol Cancer Ther August 1 2008 7 (8) 2308-2318; DOI:10.1158/1535-7163.MCT-08-0279

  • Research Articles: Therapeutics, Targets, and Development
    Elesclomol induces cancer cell apoptosis through oxidative stress
    Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam, Jane Kepros, Chin-Yu Yang, Mei Zhang, Zhenjian Du, James Barsoum and John Bertin
    Mol Cancer Ther August 1 2008 7 (8) 2319-2327; DOI:10.1158/1535-7163.MCT-08-0298

  • Research Articles: Therapeutics, Targets, and Development
    Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms
    Sharmila Shankar, Qinghe Chen, Suthakar Ganapathy, Karan P. Singh and Rakesh K. Srivastava
    Mol Cancer Ther August 1 2008 7 (8) 2328-2338; DOI:10.1158/1535-7163.MCT-08-0216

  • Research Articles: Therapeutics, Targets, and Development
    BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
    Justin L. Mott, Steve F. Bronk, Ruben A. Mesa, Scott H. Kaufmann and Gregory J. Gores
    Mol Cancer Ther August 1 2008 7 (8) 2339-2347; DOI:10.1158/1535-7163.MCT-08-0285

  • Research Articles: Therapeutics, Targets, and Development
    Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
    Tadas Vasaitis, Aashvini Belosay, Adam Schayowitz, Aakanksha Khandelwal, Pankaj Chopra, Lalji K. Gediya, Zhiyong Guo, Hong-Bin Fang, Vincent C.O. Njar and Angela M.H. Brodie
    Mol Cancer Ther August 1 2008 7 (8) 2348-2357; DOI:10.1158/1535-7163.MCT-08-0230

  • Research Articles: Therapeutics, Targets, and Development
    Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines
    Magdalena Zajac, Maria Victoria Moneo, Amancio Carnero, Javier Benitez and Beatriz Martínez-Delgado
    Mol Cancer Ther August 1 2008 7 (8) 2358-2366; DOI:10.1158/1535-7163.MCT-08-0327

  • Research Articles: Therapeutics, Targets, and Development
    SN52, a novel nuclear factor-κB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation
    Yong Xu, Fang Fang, Daret K. St. Clair, Pradoldej Sompol, Sajni Josson and William H. St. Clair
    Mol Cancer Ther August 1 2008 7 (8) 2367-2376; DOI:10.1158/1535-7163.MCT-08-0238

  • Research Articles: Therapeutics, Targets, and Development
    Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
    Zhenfeng Duan, Edward J. Weinstein, Diana Ji, Rachel Y. Ames, Edwin Choy, Henry Mankin and Francis J. Hornicek
    Mol Cancer Ther August 1 2008 7 (8) 2377-2385; DOI:10.1158/1535-7163.MCT-08-0316

  • Research Articles: Therapeutics, Targets, and Development
    Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening
    Da-Hua Fu, Wei Jiang, Jian-Ting Zheng, Gui-Yu Zhao, Yan Li, Hong Yi, Zhuo-Rong Li, Jian-Dong Jiang, Ke-Qian Yang, Yanchang Wang and Shu-Yi Si
    Mol Cancer Ther August 1 2008 7 (8) 2386-2393; DOI:10.1158/1535-7163.MCT-08-0035

  • Research Articles: Therapeutics, Targets, and Development
    Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
    Alessandra Blasina, Jill Hallin, Enhong Chen, Maria Elena Arango, Eugenia Kraynov, James Register, Stephan Grant, Sacha Ninkovic, Ping Chen, Tim Nichols, Patrick O'Connor and Kenna Anderes
    Mol Cancer Ther August 1 2008 7 (8) 2394-2404; DOI:10.1158/1535-7163.MCT-07-2391

  • Research Articles: Therapeutics, Targets, and Development
    The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
    Szu-Chieh Mei and Rong-Tsun Wu
    Mol Cancer Ther August 1 2008 7 (8) 2405-2414; DOI:10.1158/1535-7163.MCT-07-2398

  • Research Articles: Therapeutics, Targets, and Development
    New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine
    Stephan A. Veltkamp, Dick Pluim, Maria A.J. van Eijndhoven, Maria J. Bolijn, Felix H.G. Ong, Rajgopal Govindarajan, Jashvant D. Unadkat, Jos H. Beijnen and Jan H.M. Schellens
    Mol Cancer Ther August 1 2008 7 (8) 2415-2425; DOI:10.1158/1535-7163.MCT-08-0137

  • Research Articles: Therapeutics, Targets, and Development
    IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents
    Anne-Marie Liberatore, Hélène Coulomb, Dominique Pons, Olivier Dutruel, Philip G. Kasprzyk, Mark Carlson, Ann Savola Nelson, Simon P. Newman, Chloe Stengel, Pierrïck Auvray, Vincent Hesry, Béatrice Foll, Nadine Narboux, Delphine Morlais, Mélissa Le Moing, Sonia Bernetiere, Raphael Dellile, Jose Camara, Eric Ferrandis, Dennis C. Bigg and Grégoire P. Prévost
    Mol Cancer Ther August 1 2008 7 (8) 2426-2434; DOI:10.1158/1535-7163.MCT-08-0208

  • Research Articles: Therapeutics, Targets, and Development
    Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
    L.W. Lawrence Woo, Delphine S. Fischer, Christopher M. Sharland, Melanie Trusselle, Paul A. Foster, Surinder K. Chander, Anna Di Fiore, Claudiu T. Supuran, Giuseppina De Simone, Atul Purohit, Michael J. Reed and Barry V.L. Potter
    Mol Cancer Ther August 1 2008 7 (8) 2435-2444; DOI:10.1158/1535-7163.MCT-08-0195

  • Research Articles: Therapeutics, Targets, and Development
    Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
    Jirouta Kitagaki, Keli K. Agama, Yves Pommier, Yili Yang and Allan M. Weissman
    Mol Cancer Ther August 1 2008 7 (8) 2445-2454; DOI:10.1158/1535-7163.MCT-08-0063

  • Research Articles: Therapeutics, Targets, and Development
    High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis
    Jonathan Low, Shuguang Huang, Wayne Blosser, Michele Dowless, John Burch, Blake Neubauer and Louis Stancato
    Mol Cancer Ther August 1 2008 7 (8) 2455-2463; DOI:10.1158/1535-7163.MCT-08-0328

  • Research Articles: Therapeutics, Targets, and Development
    Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
    Ute Distler, Jamal Souady, Marcel Hülsewig, Irena Drmić-Hofman, Jörg Haier, Axel Denz, Robert Grützmann, Christian Pilarsky, Norbert Senninger, Klaus Dreisewerd, Stefan Berkenkamp, M. Alexander Schmidt, Jasna Peter-Katalinić and Johannes Müthing
    Mol Cancer Ther August 1 2008 7 (8) 2464-2475; DOI:10.1158/1535-7163.MCT-08-0353

  • Research Articles: Therapeutics, Targets, and Development
    Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma
    Luigia Longo, Francesca Platini, Anna Scardino, Oscar Alabiso, Giuseppe Vasapollo and Luciana Tessitore
    Mol Cancer Ther August 1 2008 7 (8) 2476-2485; DOI:10.1158/1535-7163.MCT-08-0361

  • Research Articles: Therapeutics, Targets, and Development
    Anti-CD30 diabody-drug conjugates with potent antitumor activity
    Kristine M. Kim, Charlotte F. McDonagh, Lori Westendorf, Lindsay L. Brown, Django Sussman, Tiffany Feist, Robert Lyon, Stephen C. Alley, Nicole M. Okeley, Xinqun Zhang, Melissa C. Thompson, Ivan Stone, Hans-Peter Gerber and Paul J. Carter
    Mol Cancer Ther August 1 2008 7 (8) 2486-2497; DOI:10.1158/1535-7163.MCT-08-0388

  • Research Articles: Therapeutics, Targets, and Development
    Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool
    Thomas Falguières, Matthias Maak, Claus von Weyhern, Marianne Sarr, Xavier Sastre, Marie-France Poupon, Sylvie Robine, Ludger Johannes and Klaus-Peter Janssen
    Mol Cancer Ther August 1 2008 7 (8) 2498-2508; DOI:10.1158/1535-7163.MCT-08-0430

  • Research Articles: Therapeutics, Targets, and Development
    Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN
    Sarah A. Martin and Toru Ouchi
    Mol Cancer Ther August 1 2008 7 (8) 2509-2516; DOI:10.1158/1535-7163.MCT-08-0199

  • Research Articles: Therapeutics, Targets, and Development
    Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
    John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang and John R. Desjarlais
    Mol Cancer Ther August 1 2008 7 (8) 2517-2527; DOI:10.1158/1535-7163.MCT-08-0201

  • Research Articles: Therapeutics, Targets, and Development
    Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing
    Abujiang Pataer, Wenxian Hu, Lu Xiaolin, Sunil Chada, Jack A. Roth, Kelly K. Hunt and Stephen G. Swisher
    Mol Cancer Ther August 1 2008 7 (8) 2528-2535; DOI:10.1158/1535-7163.MCT-08-0083

  • Research Articles: Therapeutics, Targets, and Development
    Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G. Bagley, Cecile Rouleau, Thia St. Martin, Paula Boutin, William Weber, Melanie Ruzek, Nakayuki Honma, Mariana Nacht, Srinivas Shankara, Shiro Kataoka, Isao Ishida, Bruce L. Roberts and Beverly A. Teicher
    Mol Cancer Ther August 1 2008 7 (8) 2536-2546; DOI:10.1158/1535-7163.MCT-08-0050

  • Research Articles: Therapeutics, Targets, and Development
    Tumor necrosis factor-α–induced accentuation in cryoinjury: mechanisms in vitro and in vivo
    Jing Jiang, Raghav Goel, M. Arif Iftekhar, Rachana Visaria, John D. Belcher, Gregory M. Vercellotti and John C. Bischof
    Mol Cancer Ther August 1 2008 7 (8) 2547-2555; DOI:10.1158/1535-7163.MCT-07-2421

  • Research Articles: Therapeutics, Targets, and Development
    Fatty acid synthase inhibition results in a magnetic resonance–detectable drop in phosphocholine
    James Ross, Amer M. Najjar, Madhuri Sankaranarayanapillai, William P. Tong, Kumaralal Kaluarachchi and Sabrina M. Ronen
    Mol Cancer Ther August 1 2008 7 (8) 2556-2565; DOI:10.1158/1535-7163.MCT-08-0015

  • Research Articles: Therapeutics, Targets, and Development
    Relaxin treatment of solid tumors: effects on electric field–mediated gene delivery
    Joshua Henshaw, Brian Mossop and Fan Yuan
    Mol Cancer Ther August 1 2008 7 (8) 2566-2573; DOI:10.1158/1535-7163.MCT-08-0435

Back to top
PreviousNext
Molecular Cancer Therapeutics: 7 (8)
August 2008
Volume 7, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool

Jump to

  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement